Lbp Am Sa Takes Position in Edwards Lifesciences Corporation $EW

Key Points

• Lbp Am Sa has acquired a new stake in Edwards Lifesciences Corporation, purchasing 17,101 shares valued at approximately $1,337,000 in the second quarter.
• Several institutional investors have increased their holdings in Edwards Lifesciences, with 79.46% of the stock now owned by institutional investors and hedge funds.
• Research analysts are generally positive on Edwards Lifesciences, with ratings including several "strong-buy" and "buy," and an average target price of $86.61 for the stock.

Lbp Am Sa acquired a new stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 17,101 shares of the medical research company's stock, valued at approximately $1,337,000.

Other institutional investors have also modified their holdings of the company. Arlington Trust Co LLC boosted its holdings in Edwards Lifesciences by 1.2% in the first quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company's stock valued at $804,000 after purchasing an additional 135 shares during the period. Valeo Financial Advisors LLC boosted its holdings in Edwards Lifesciences by 2.8% in the first quarter. Valeo Financial Advisors LLC now owns 5,136 shares of the medical research company's stock valued at $372,000 after purchasing an additional 142 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in Edwards Lifesciences by 0.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock valued at $2,170,000 after purchasing an additional 145 shares during the period. Dakota Wealth Management boosted its holdings in Edwards Lifesciences by 2.5% in the second quarter. Dakota Wealth Management now owns 6,048 shares of the medical research company's stock valued at $473,000 after purchasing an additional 146 shares during the period. Finally, Leo Wealth LLC boosted its holdings in Edwards Lifesciences by 1.2% in the first quarter. Leo Wealth LLC now owns 12,488 shares of the medical research company's stock valued at $905,000 after purchasing an additional 150 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on EW shares. The Goldman Sachs Group reiterated a "buy" rating on shares of Edwards Lifesciences in a report on Friday, July 25th. Barclays lifted their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the stock an "overweight" rating in a report on Friday, July 25th. Wall Street Zen downgraded Edwards Lifesciences from a "strong-buy" rating to a "buy" rating in a report on Monday. Daiwa America raised Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, July 29th. Finally, Evercore ISI lifted their price target on Edwards Lifesciences from $77.00 to $80.00 and gave the stock an "in-line" rating in a report on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $86.61.

Insider Transactions at Edwards Lifesciences

In other news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the sale, the vice president owned 22,002 shares in the company, valued at $1,748,278.92. This trade represents a 15.75% decrease in their position. The disclosure for this sale can be found here. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Stock Up 0.5%

EW opened at $76.66 on Friday. The business's 50-day simple moving average is $78.55 and its 200-day simple moving average is $75.89. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. Edwards Lifesciences Corporation has a one year low of $64.00 and a one year high of $83.00. The stock has a market capitalization of $45.01 billion, a P/E ratio of 11.03, a price-to-earnings-growth ratio of 3.67 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.49 billion. During the same quarter in the previous year, the firm earned $0.70 earnings per share. The business's revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.